Stroke prevention: Modifying risk factors

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 4, 2008, Pages 287-303

  Romero, José Rafael ^a   Morris, Jane ^b   Pikula, Aleksandra ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Stroke Prevention; Traditional Risk Factors

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APIXABAN; ATENOLOL; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DU 176B; ENOXAPARIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LOSARTAN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NICOTINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; RAMIPRIL; RIVAROXABAN; ROSIGLITAZONE; UNINDEXED DRUG; VARENICLINE; WARFARIN; XIMELAGATRAN; YM 150;

BLEEDING; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MONOTHERAPY; NAUSEA; OBESITY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; STROKE; TOBACCO DEPENDENCE;

ATRIAL FIBRILLATION; CAROTID ARTERY DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; OBESITY; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; STROKE;

EID: 68749122261     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708093847     Document Type: Review

References (100)

1. Accord-Study-Group. (2008 ) Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358: 2545-2559.
2. Albucher, J.F., Ferrieres, J., Ruidavets, J.B., Guiraud-Chaumeil, B., Perret, B.P., Chollet, F. (2000) Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry 69: 29-33.
3. Alvarez-Sabin, J., Huertas, R., Quintana, M., Rubiera, M., Delgado, P., Ribo, M. et al. (2007) Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 38: 1076-1078.
4. Amarenco, P. (2005) Effect of statins in stroke prevention. Curr Opin Lipidol 16: 614-618.
5. Amarenco, P., Bogousslavsky, J., Callahan, A., 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E. et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549-559.
6. Arauz-Pacheco, C., Parrott, M.A. and Raskin, P. (2002) The treatment of hypertension in adult patients with diabetes. Diabetes Care 25: 134-147.
7. Athyros, V.G., Papageorgiou, A.A., Mercouris, B.R., Athyrou, V.V., Symeonidis, A.N., Basayannis, E.O. et al. (2002) Treatment with atorvastatin to the national cholesterol educational program goal vs. ‘usual’ care in secondary coronary heart disease prevention. The greek atorvastatin and coronary-heart-disease evaluation (Greace) study. Curr Med Res Opin 18: 220-228.
8. Atrial-Fibrillation-Investigators. (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154: 1449-1457.
9. Blanco, M., Nombela, F., Castellanos, M., Rodriguez-Yanez, M., Garcia-Gil, M., Leira, R. et al. (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69: 904-910.
10. Bodenheimer, T. (2007) A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans. Jama 298: 2048-2055.
11. Bruno, A., Levine, S.R., Frankel, M.R., Brott, T.G., Lin, Y., Tilley, B.C. et al. (2002) Admission glucose level and clinical outcomes in the ninds Rt-Pa stroke trial. Neurology 59: 669-674.
12. Cdc. (2004) Cigarette smoking among adults - United States, 2002. Morbidity and Mortality Weekly Report. Vol. 53: 427-431.
13. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr, J.L. et al. (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the Jnc 7 report. Jama 289: 2560-2572.
14. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (Cards): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
15. Collins, R., Armitage, J., Parish, S., Sleight, P. and Peto, R. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757-767.
16. Colwell, J.A. (1997) Aspirin therapy in diabetes. Diabetes Care 20: 1767-1771.
17. Curb, J.D., Abbott, R.D., Rodriguez, B.L., Masaki, K.H., Chen, R., Popper, J.S. et al. (2004) High density lipoprotein cholesterol and the risk of stroke in elderly men: the honolulu heart program. Am J Epidemiol 160: 150-157.
18. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (Life): A randomised trial against atenolol. Lancet 359: 995-1003.
19. Deplanque, D., Leys, D., Parnetti, L., Schmidt, R., Ferro, J., de Reuck, J. et al. (2006) Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge. Cerebrovasc Dis 21: 372-379.
20. Deplanque, D., Masse, I., Lefebvre, C., Libersa, C., Leys, D. and Bordet, R. (2006) Prior tia, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology 67: 1403-1410.
21. Dobkin, B. (1995) The economic impact of stroke. Neurology 45: S6-S9.
22. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366: 1279-1289.
23. Elkind, M.S., Flint, A.C., Sciacca, R.R. and Sacco, R.L. (2005) Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 65: 253-258.
24. Endres, M. (2005) Statins and stroke. J Cereb Blood Flow Metab 25: 1093-1110.
25. Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N. and Schrier, R.W. (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645-652.
26. European-Atrial-Fibrillation-Trial-Investigators. (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Eaft (European Atrial Fibrillation Trial) Study Group. Lancet 342: 1255-1262.
27. Fisher, W.D., Eriksson, B.I., Bauer, K.A., Borris, L., Dahl, O.E., Gent, M. et al. (2007) Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 97: 931-937.
28. Flegal, K.M., Carroll, M.D., Ogden, C.L. and Johnson, C.L. (2002) Prevalence and trends in obesity among us adults, 1999-2000. Jama 288: 1723-1727.
29. Flegal, K.M., Graubard, B.I., Williamson, D.F. and Gail, M.H. (2005) Excess deaths associated with underweight, overweight, and obesity. Jama 293: 1861-1867.
30. Genuth, S., Alberti, K.G., Bennett, P., Buse, J., Defronzo, R., Kahn, R. et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160-3167.
31. Gerstein, H.C., Yusuf, S., Bosch, J., Pogue, J., Sheridan, P., Dinccag, N. et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096-1105.
32. Go, A.S., Hylek, E.M., Chang, Y., Phillips, K.A., Henault, L.E., Capra, A.M. et al. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? Jama 290: 2685-2692.
33. Goldstein, L.B., Adams, R., Alberts, M.J., Appel, L.J., Brass, L.M., Bushnell, C.D. et al. (2006) primary prevention of ischemic stroke: a guideline from the American heart association / American stroke association stroke council: cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: the American academy of neurology affirms the value of this guideline. Stroke 37: 1583-1633.
34. Gonzales, D., Rennard, S.I., Nides, M., Oncken, C., Azoulay, S., Billing, C.B. et al. (2006) Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, Vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial. Jama 296: 47-55.
35. Haffner, S.M. (1998) Management of dyslipidemia in adults with diabetes. Diabetes Care 21: 160-178.
36. Hajjar, I., Kotchen, J.M. and Kotchen, T.A. (2006) Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 27: 465-490.
37. Hampton, T. (2006) Researchers draft guidelines for clinical use of pharmacogenomics. Jama 296: 1453-1454.
38. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (Hot) randomised trial. Hot study group. Lancet 351: 1755-1762.
39. Hickenbottom, S.L., Fendrick, A.M., Kutcher, J.S., Kabeto, M.U., Katz, S.J., Langa, K.M. (2002) A national study of the quantity and cost of informal caregiving for the elderly with stroke. Neurology 58: 1754-1759.
40. Hope-Study-Investigators. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. Heart outcomes prevention evaluation study investigators. Lancet 355: 253-259.
41. Hylek, E.M., Skates, S.J., Sheehan, M.A. and Singer, D.E. (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335: 540-546.
42. Ikram, M.A., Vernooij, M.W., Hofman, A., Niessen, W.J., van der Lugt, A. and Breteler, M.M. (2008) Kidney function is related to cerebral small vessel disease. Stroke 39: 55-61.
43. Jorenby, D.E., Leischow, S.J., Nides, M.A., Rennard, S.I., Johnston, J.A., Hughes, A.R. et al. (1999) A Controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-691.
44. Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N. et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354: 1685-1697.
45. Kaarisalo, M.M., Raiha, I., Arve, S. and Lehtonen, A. (2006) Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years. Age Ageing 35: 592-596.
46. Kannel, W.B. (2000) Risk Stratification in Hypertension: new insights from the framingham study. Am J Hypertens 13: 3S-10S.
47. Kernan, W.N., Inzucchi, S.E., Viscoli, C.M., Brass, L.M., Bravata, D.M. and Horwitz, R.I. (2002) Insulin resistance and risk for stroke. Neurology 59: 809-815.
48. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A. et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
49. Lancaster, T., Stead, L., Silagy, C. and Sowden, A. (2000) Effectiveness of interventions to help people stop smoking: findings from the cochrane library. Bmj 321: 355-358.
50. Levine, M.N., Raskob, G., Beyth, R.J., Kearon, C. and Schulman, S. (2004) Hemorrhagic complications of anticoagulant treatment: the seventh accp conference on antithrombotic and thrombolytic therapy. Chest 126: 287S-310S.
51. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913.
52. Lin, H.J., Wolf, P.A., Kelly-Hayes, M., Beiser, A.S., Kase, C.S., Benjamin, E.J. et al. (1996) Stroke severity in atrial fibrillation. The framingham study. Stroke 27: 1760-1764.
53. Linder, M.W., Looney, S., Adams, J.E., 3rd, Johnson, N., Antonino-Green, D., Lacefield, N. et al. (2002) Warfarin dose adjustments based on cyp2c9 genetic polymorphisms. J Thromb Thrombolysis 14: 227-232.
54. Lindstrom, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J.G., Hemio, K. et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the finnish diabetes prevention study. Lancet 368: 1673-1679.
55. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S. et al. (2004) Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation 110: 1042-1046.
56. Man-Son-Hing, M. and Laupacis, A. (2003) Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 163: 1580-1586.
57. Man-Son-Hing, M., Nichol, G., Lau, A. and Laupacis, A. (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159: 677-685.
58. Mungall, D. (2002) Bibr-1048 boehringer ingelheim. Curr Opin Investig Drugs 3: 905-907.
59. National-Diabetes-Statistics-Niddk. (2005) National diabetes statistics; total prevalence of diabetes in the United States, all ages, 2005. In: Niddk, N.I.O.H.U.S.D.O.H.A.H.S., ed: NIH
60. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
61. Olsson, S.B. (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (Sportif III): randomised controlled trial. Lancet 362: 1691-1698.
62. Ovbiagele, B. and Saver, J.L. (2006) Ensuring management of vascular risk factors after stroke. Rev Neurol Dis 3: 93-100.
63. Papademetriou, V., Farsang, C., Elmfeldt, D., Hofman, A., Lithell, H., Olofsson, B. et al. (2004) Stroke prevention with the angiotensin ii type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (Scope). J Am Coll Cardiol 44: 1175-1180.
64. Parsons, M.W., Barber, P.A., Desmond, P.M., Baird, T.A., Darby, D.G., Byrnes, G. et al. (2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52: 20-28.
65. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E.D. and Andersen, B. (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak Study. Lancet 1: 175-179.
66. Prochazka, A.V., Weaver, M.J., Keller, R.T., Fryer, G.E., Licari, P.A. and Lofaso, D. (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158: 2035-2039.
67. Progress-Collaborative-Group. (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
68. Pyorala, M., Miettinen, H., Halonen, P., Laakso, M. and Pyorala, K. (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the helsinki policemen study. Arterioscler ThrombVasc Biol 20: 538-544.
69. Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., Mcleod, H.L. et al. (2005) Effect of vkorc 1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352: 2285-2293.
70. Rodgers, A., Macmahon, S., Gamble, G., Slattery, J., Sandercock, P. and Warlow, C. (1996) Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom transient ischaemic attack collaborative group. Bmj 313: 147.
71. Rosamond, W., Faha, K., Furie, K., Go, A., Greenlund, K., Haase, N. et al. (2008) Heart disease and stroke statistics-2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 117: e25-e146.
72. Ryden, L., Standl, E., Bartnik, M., van den Berghe, G., Betteridge, J., de Boer, M.J. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive Summary. The task force on diabetes and cardiovascular diseases of the european society of cardiology (Esc) and of the European Association for the Study of Diabetes (Easd). Eur Heart J 28: 88-136.
73. Sacco, R.L. (2001) Clinical practice. Extracranial carotid stenosis. N Engl J Med 345: 1113-1118.
74. Sacco, R.L., Adams, R., Albers, G., Alberts, M.J., Benavente, O., Furie, K. et al. (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association / American stroke association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention: the American academy of neurology affirms the value of this guideline. Stroke 37: 577-617.
75. Sandercock, P., Bamford, J., Dennis, M., Burn, J., Slattery, J., Jones, L. et al. (1992) Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (oxfordshire community stroke project). Bmj 305: 1460-1465.
76. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P. et al. (2005) The impact of Cyp2c9 and vkorc 1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106: 2329-2333.
77. Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (Ascot-Lla): A multicentre randomised controlled trial. Lancet 361: 1149-1158.
78. Shahar, E., Chambless, L.E., Rosamond, W.D., Boland, L.L., Ballantyne, C.M., Mcgovern, P.G. et al. (2003) Plasma lipid profile and incident ischemic stroke: the atherosclerosis risk in communities (aric) study. Stroke 34: 623-631.
79. Shinton, R. and Beevers, G. (1989) Meta-analysis of relation between cigarette smoking and stroke. Bmj 298: 789-794.
80. Silagy, C., Mant, D., Fowler, G. and Lancaster, T. (2000) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146.
81. Spaf-Iii-Trial-Investigators. (1996) Adjusted-dose warfarin vs. low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation iii randomised clinical trial. Lancet 348: 633-638.
82. Suk, S.H., Sacco, R.L., Boden-Albala, B., Cheun, J.F., Pittman, J.G., Elkind, M.S. et al. (2003) Abdominal obesity and risk of ischemic stroke: the northern manhattan stroke study. Stroke 34: 1586-1592.
83. Tall, A.R. (1990) Plasma high density lipoproteins. metabolism and relationship to atherogenesis. J Clin Invest 86: 379-384.
84. The-Expert-Committee-on-the-Diagnosis-and-Classification-of-Diabetes-Mellitus. (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183-1197.
85. The Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (2002) Third report of the national cholesterol education program (Ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Iii) final report. Circulation 106: 3143-3421.
86. Thom, T., Haase, N., Rosamond, W., Howard, V.J., Rumsfeld, J., Manolio, T. et al. (2006) Heart Disease and Stroke Statistics-2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113: e85-151.
87. Tirschwell, D.L., Smith, N.L., Heckbert, S.R., Lemaitre, R.N., Longstreth Jr, W.T., Psaty, B.M. (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63: 1868-1875.
88. Turpie, A.G. (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29: 155-165.
89. Ukpds-Group-Investigators. (1998 a) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (Ukpds 33). Uk prospective diabetes study (Ukpds) group. Lancet 352: 837-853.
90. Ukpds-Group-Investigators. (1998 b) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 38. Uk prospective diabetes study group. Bmj 317: 703-713.
91. Vasan, R.S., Beiser, A., Seshadri, S., Larson, M.G., Kannel, W.B., D'agostino, R.B. et al. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. Jama 287: 1003-1010.
92. Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'donnell, C.J., Kannel, W.B. et al. (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291-1297.
93. Vermeer, S.E., Sandee, W., Algra, A., Koudstaal, P.J., Kappelle, L.J. and Dippel, D.W. (2006) Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 37: 1413-1417.
94. Voko, Z., Hollander, M., Koudstaal, P.J., Hofman, A. and Breteler, M.M. (2004) How do american stroke risk functions perform in a western european population? Neuroepidemiology 23: 247-253.
95. Wattigney, W.A., Mensah, G.A. and Croft, J.B. (2003) Increasing trends in hospitalization for atrial fibrillation in the united states, 1985 through 1999: implications for primary prevention. Circulation 108: 711-716.
96. Williams, G.R. (2001) Incidence and characteristics of total stroke in the United States. BMC Neurol 1: 2.
97. Wolf, P.A. (2004) Epidemiology of Stroke. In: Mohr, J.P., Dennis, W.C., Grotta, J.C. and Wolf, P.A. (ed.) Stroke, pathophysiology, diagnosis, and management, Vol. 1. 4th edn: Elsevier Publishing: Boston, pp. 13-34.
98. Wolf, P.A., Abbott, R.D. and Kannel, W.B. (1991) Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke 22: 983-988.
99. Wolf, P.A., D'agostino, R.B., Belanger, A.J. and Kannel, W.B. (1991) Probability of stroke: A risk profile from the framingham study. Stroke 22: 312-318.
100. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an Angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342: 145-153.